The service
One oncology decision, clarified in five days.
A one-off pilot for one asset, one indication and one decision question. You receive a sourced brief, concrete options and one written revision.
Oncology competitive intelligence turns public evidence about rival programmes into an answer for a decision on your own asset. Big pharma assigns this work to an internal team; smaller biotechs often have the data but not the time to frame and answer the question.
Prognyx starts with a bounded pilot: one asset, one indication and one decision question, delivered in five business days at a fixed fee agreed in writing.
Who this is for
Prognyx fits a specific shape of company, and says so plainly because a bad fit wastes both our time:
- Clinical-stage oncology biotechs, typically Series B and later or newly listed, with one or two assets that carry the company's value.
- No internal CI function, the work currently lands on a CBO, a head of BD, or a CMO who is doing it at 11pm on top of their real job.
- A real competitive threat with a date on it: a rival readout, a PDUFA, a congress presentation, a filing window.
- Oncology. Only oncology. A generalist watching twelve therapeutic areas cannot tell you what a hazard ratio of 0.76 with no p-value means for your filing strategy.
It is a poor fit if you already run a staffed CI team with platform subscriptions, in that case you need tooling to make your analysts faster, not another analyst. And it is a poor fit if you need coverage across many therapeutic areas.
What you get
A written question
We agree one asset, one indication and the exact decision the pilot must clarify before work begins.
A bounded competitive set
We identify the rival programmes, trials, readouts and milestones that directly affect that question.
A five-day brief
Within five business days, you receive the evidence, implications, dated milestones and the practical options available.
An executive read
The brief is written to be forwarded to a board member or partner without another layer of analysis.
Everything traced
Every factual claim links to the primary record, NCT number, filing, label, abstract. You can verify the whole brief without taking a word on trust.
One revision
One written revision is included to correct the framing or clarify the analysis within the agreed scope.
Why not a data platform
Enterprise CI platforms, Cortellis, Citeline, Evaluate, GlobalData, AlphaSense, are genuinely good at what they are for: breadth of coverage, structured data, and giving a trained analyst a place to work. They are the right purchase when you have analysts.
The mismatch for a single-asset biotech is not quality, it is shape. A platform sells you access and leaves the analysis to you; the cost that actually hurts is not the licence fee but the senior hours spent mining it. And the licence fee is designed for a company with a CI department to amortise it across.
If you are actively comparing, the honest side-by-side is here: Prognyx vs Cortellis and Prognyx vs AlphaSense, including what each does better than Prognyx.
Why not a consulting project
A boutique CI consultancy will produce an excellent landscape assessment, once, for somewhere in the region of a mid-five-figure project fee. It is the right purchase for a discrete strategic question with a decision date, a licensing evaluation, a go/no-go.
For a narrow, time-sensitive question, a large consulting project can be more scope than the buyer needs. The Prognyx pilot fixes the question and evidence set in writing, then delivers the decision brief in five business days. If the question is broad enough to require a full landscape project, we say so before work starts.
Why not do it in-house
Plenty of companies do, and for the first while it works: your CSO knows the field better than any outside analyst and can hold the important twenty trials in her head. The failure mode is not competence, it is attention. The watch is the first thing dropped when a manufacturing issue or a financing lands, and it is dropped silently, you don't find out the watch lapsed until the competitor's abstract is already public.
The realistic comparison is not Prognyx versus a full-time analyst hire. It is Prognyx versus the version of this work that currently happens on nights and weekends, inconsistently.
How the pilot works
One-off pilot · written scope · no subscription
5 business days · fixed fee
One asset, one indication and one defined decision question. Within five business days, you receive a sourced brief covering relevant competitor programmes, trials and milestones, implications, available options and one written revision.
How an engagement starts
- Read the public example. The complete sample shows the structure, sourcing standard and depth before you contact us.
- Define the pilot in writing. Tell us the asset, indication and decision question. We confirm the exact scope, delivery date and fee in writing before payment.
- Receive and review the brief. We deliver within five business days and include one written revision. Ongoing monitoring is discussed only if the pilot reveals a recurring need.
The pilot is a single engagement at a fixed fee, not a subscription. Any later monitoring agreement has its own written scope and fee.
What Prognyx is not
It is not a platform, not a dashboard, and not a login. It is not medical or investment advice, see terms. It is not a generalist CI shop that also covers oncology. And it is not anonymous: Rali Filali writes and audits every brief and puts his name on it, which is the whole point of buying a person rather than a subscription. The procedure that keeps the work honest is published on how we work.
Frequently asked
What is competitive intelligence in pharma?
Competitive intelligence in pharma is the continuous collection and analysis of public information about rival drug programmes, clinical trials, regulatory actions, corporate disclosures, publications and congress data, to inform strategic decisions about your own asset. It is not market research and not surveillance: everything used is public. The output is a read on how a competitor's move changes your positioning, and what to do about it.
How is a Prognyx pilot priced?
Each pilot is one fixed fee, confirmed in writing with the scope and delivery date before any work or payment. It covers one asset, one indication and one decision question, with delivery in five business days and one written revision. Ongoing monitoring is scoped separately only after a useful pilot.
How is this different from a competitive intelligence platform?
A platform sells access to data and leaves the analysis to your team; it assumes you have analysts. Prognyx sells the analysis, the watch, the judgement and the "what to do", and assumes you don't. If you have a staffed CI team, buy the platform. If the work currently lands on your CBO at 11pm, buy the function.
Which therapeutic areas does Prognyx cover?
Oncology only, and that is deliberate. Depth in one field is what makes it possible to say something useful about a specific hazard ratio, endpoint or regulatory precedent. Prognyx will decline work outside oncology rather than cover it thinly.
Do I have to share confidential data?
No. Scoping needs your assets, mechanisms and indications, normally already public in your pipeline page or filings. Prognyx does not need and does not ask for unpublished results or internal strategy documents to do the watch.
How fast is the pilot delivered?
The pilot is delivered within five business days of the agreed start. If the evidence cannot support the question, that limitation is stated directly rather than filled with speculation.
Does the pilot become a subscription?
No. The pilot is paid once and ends after delivery and the included revision. If the work reveals a recurring monitoring need, we define a separate scope and fee; nothing renews automatically.
Start with one decision.
Name the asset, indication and decision to clarify. We will confirm the pilot scope and fee in writing.
Scope a pilot → Read five published briefings